Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | HRMY | RXRX |
|---|---|---|
| Price | $39.92 | $4.78 |
| Change today | ▲ 0.71% | ▲ 16.02% |
| Market cap | $2.32B | $2.56B |
| Return, 3 months | +4.3% | +24.5% |
| Return, year to date | +6.7% | +16.9% |
| Return, 1 year | +50.1% | -13.6% |
| P/E (TTM) | 12.9 | -4.8 |
| P/B | 2.3 | 2.8 |
| P/E percentile vs own 5y | 41st | 49th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | – | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | – | – |
| Analyst target vs. price | +16.3% | +39.1% |
| Analyst buy share | 57% | 40% |
| RSI (14) | 47 | 72 |
| 30-day volatility | 27.4% | 89.6% |
| Max drawdown, 1 year | -34.5% | -58.2% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
